DK2066791T3 - Genterapi for amyotrofisk lateralsklerose og andre rygmarvssygdomme - Google Patents

Genterapi for amyotrofisk lateralsklerose og andre rygmarvssygdomme

Info

Publication number: DK2066791T3
Authority: DK; Denmark
Prior art keywords: gene therapy; spinal cord; lateral sclerosis; amyotrophic lateral; cord diseases
Prior art date: 2006-10-03

Application number

DK07839216.4T

Other languages

English (en)

Inventor

Samuel Wadsworth

Catherine O'riordan

Original Assignee

Genzyme Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-03

Filing date

2007-10-03

Publication date

2012-10-15

2007-10-03 Application filed by Genzyme Corp filed Critical Genzyme Corp

2012-10-15 Application granted granted Critical

2012-10-15 Publication of DK2066791T3 publication Critical patent/DK2066791T3/da

Links

208000029033 Spinal Cord disease Diseases 0.000 title 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 title 1
238000001415 gene therapy Methods 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6027—Vectors comprising as targeting moiety peptide derived from defined protein from viruses ssDNA viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Biotechnology (AREA)
Zoology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Biomedical Technology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Epidemiology (AREA)
Neurology (AREA)
Biochemistry (AREA)
Virology (AREA)
Gastroenterology & Hepatology (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Marine Sciences & Fisheries (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK07839216.4T 2006-10-03 2007-10-03 Genterapi for amyotrofisk lateralsklerose og andre rygmarvssygdomme DK2066791T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US82797706P	2006-10-03	2006-10-03
PCT/US2007/021272 WO2008042420A2 (en)	2006-10-03	2007-10-03	Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders

Publications (1)

Publication Number	Publication Date
DK2066791T3 true DK2066791T3 (da)	2012-10-15

Family

ID=39269037

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK12157957.7T DK2497500T3 (da)	2006-10-03	2007-10-03	Genterapi mod spinal muskelatrofi
DK07839216.4T DK2066791T3 (da)	2006-10-03	2007-10-03	Genterapi for amyotrofisk lateralsklerose og andre rygmarvssygdomme

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK12157957.7T DK2497500T3 (da)	2006-10-03	2007-10-03	Genterapi mod spinal muskelatrofi

Country Status (13)

Country	Link
US (2)	US9890394B2 (da)
EP (4)	EP2066791B1 (da)
CN (3)	CN108853517A (da)
AR (1)	AR063113A1 (da)
CY (1)	CY1118477T1 (da)
DK (2)	DK2497500T3 (da)
ES (3)	ES2757723T3 (da)
HU (2)	HUE031182T2 (da)
LT (2)	LT2497500T (da)
PL (2)	PL2066791T3 (da)
PT (3)	PT2497500T (da)
SI (3)	SI2066791T1 (da)
WO (1)	WO2008042420A2 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2066791T3 (pl)	2006-10-03	2013-02-28	Genzyme Corp	Terapia Genowa do leczenia stwardnienia zanikowego bocznego i innych zaburzeń rdzenia kręgowego
WO2009090933A1 (ja) *	2008-01-16	2009-07-23	Japan Science And Technology Agency	低酸素状態にある細胞で増殖するウイルスまたは遺伝子を発現するウイルスベクター
JP5879256B2 (ja)	2009-05-02	2016-03-08	ジェンザイム・コーポレーション	神経変性障害のための遺伝子治療
WO2013025963A2 (en)	2011-08-17	2013-02-21	President And Fellows Of Harvard College	Conversion of somatic cells into functional spinal motor neurons, and methods and uses thereof
CN119876138A (zh)	2014-11-14	2025-04-25	沃雅戈治疗公司	调节性多核苷酸
CA3193811A1 (en)	2014-11-14	2016-05-19	Voyager Therapeutics, Inc.	Compositions and methods of treating amyotrophic lateral sclerosis (als)
CA2975447C (en) *	2015-01-30	2021-02-23	The Regents Of The University Of California	Spinal subpial gene delivery system
CL2015003024A1 (es)	2015-10-09	2016-05-13	Univ Chile	Método de tratamiento genético utilizando el virus aav-xbp1s/gfp, y su uso en la prevención y tratamiento de la esclerosis lateral amiotrofica.
AU2017241534A1 (en)	2016-03-28	2018-10-04	The Regents Of The University Of California	Method and composition for treating neuronal hyper-excitability
CA3024448C (en)	2016-05-18	2025-09-09	Voyager Therapeutics, Inc.	MODULATING POLYNUCLEOTIDES
BR112019009834B1 (pt) *	2016-11-17	2022-05-17	Ohio State Innovation Foundation	Vetor viral adeno-associado recombinante (raav), vírus, composição farmacêutica e uso de um vetor raav
JOP20190200A1 (ar)	2017-02-28	2019-08-27	Univ Pennsylvania	تركيبات نافعة في معالجة ضمور العضل النخاعي
EP3618839A4 (en)	2017-05-05	2021-06-09	Voyager Therapeutics, Inc.	COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
EP3668891B1 (en) *	2017-08-16	2023-07-26	Lgv1 S.R.L.	Vtft isoform of a bpifb4 protein for use in neuronal deseases and injuries
JP7291125B2 (ja)	2017-09-08	2023-06-14	ザリージェンツオブザユニバーシティオブカリフォルニア	神経障害性疼痛を処置するための方法および組成物
TW202413649A (zh)	2017-10-16	2024-04-01	美商航海家醫療公司	肌萎縮性脊髓側索硬化症(als)之治療
WO2019079242A1 (en)	2017-10-16	2019-04-25	Voyager Therapeutics, Inc.	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
EP3908198B1 (en)	2019-01-10	2024-12-11	The Regents of the University of California	Subpial delivery system
USD963164S1 (en)	2020-01-09	2022-09-06	The Regents Of The University Of California	Surgical needle
WO2023288086A2 (en) *	2021-07-16	2023-01-19	President And Fellows Of Harvard College	Enhancers driving expression in motor neurons

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE8303626D0 (sv)	1983-06-23	1983-06-23	Kabigen Ab	A recombinant plasmid a transformant microorganism, a polydoxyrebonucleotide segment, a process for producing a biologically active protein, and the protein thus produced
US5672344A (en)	1987-12-30	1997-09-30	The Regents Of The University Of Michigan	Viral-mediated gene transfer system
ES2249761T3 (es)	1993-06-24	2006-04-01	Advec Inc.	Vectores de adenovirus para terapia genica.
EP1637608B1 (en)	1993-10-25	2009-07-22	CANJI, Inc.	Recombinant adenoviral vector and methods of use
PT733103E (pt)	1993-11-09	2004-07-30	Targeted Genetics Corp	Criacao de elevados titulos de vectores de aav recombinantes
US7252989B1 (en)	1994-04-04	2007-08-07	Board Of Regents, The University Of Texas System	Adenovirus supervector system
CA2187626C (en)	1994-04-13	2009-11-03	Michael G. Kaplitt	Aav-mediated delivery of dna to cells of the nervous system
US5882914A (en)	1995-06-06	1999-03-16	The Johns Hopkins University School Of Medicine	Nucleic acids encoding the hypoxia inducible factor-1
AU1525797A (en)	1996-04-22	1997-11-12	Medtronic, Inc.	Two-stage angled venous cannula
US6432947B1 (en)	1997-02-19	2002-08-13	Berlex Laboratories, Inc.	N-heterocyclic derivatives as NOS inhibitors
US20030104973A1 (en) *	1997-08-21	2003-06-05	Quark Biotech, Inc.	Hypoxia-regulated genes
IL136454A0 (en)	1997-12-04	2001-06-14	Genzyme Corp	Compositions and methods for inducing gene expression
US6124131A (en)	1998-08-25	2000-09-26	The Johns Hopkins University School Of Medicine	Mutant hypoxia inducible factor-1 HIF-1
US6544785B1 (en)	1998-09-14	2003-04-08	Mount Sinai School Of Medicine Of New York University	Helper-free rescue of recombinant negative strand RNA viruses
AU2001290984A1 (en)	2000-09-18	2002-04-02	Genzyme Corporation	Expression vectors containing hybrid ubiquitin promoters
US6838430B2 (en) *	2001-09-28	2005-01-04	The Regents Of The University Of California	Use of HIF-1a variants to accelerate wound healing
NZ533833A (en) *	2001-12-21	2008-01-31	Salk Inst For Biological Studi	Targeted retrograde gene delivery to motor neurons
US7193053B2 (en) *	2003-04-25	2007-03-20	United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Hypoxia-inducible factor 1alpha variants and methods of use
GB2414934A (en) *	2004-06-11	2005-12-14	Gill Steven Streatfield	Treatment of Parkinson's disease with GDNF
PL2066791T3 (pl)	2006-10-03	2013-02-28	Genzyme Corp	Terapia Genowa do leczenia stwardnienia zanikowego bocznego i innych zaburzeń rdzenia kręgowego
RU2640115C2 (ru)	2011-11-01	2017-12-26	Ресверлоджикс Корп.	Фармацевтические композиции замещенных хиназолинонов

2007
- 2007-10-03 PL PL07839216T patent/PL2066791T3/pl unknown
- 2007-10-03 WO PCT/US2007/021272 patent/WO2008042420A2/en not_active Ceased
- 2007-10-03 PL PL12157957T patent/PL2497500T3/pl unknown
- 2007-10-03 EP EP07839216A patent/EP2066791B1/en active Active
- 2007-10-03 PT PT121579577T patent/PT2497500T/pt unknown
- 2007-10-03 DK DK12157957.7T patent/DK2497500T3/da active
- 2007-10-03 DK DK07839216.4T patent/DK2066791T3/da active
- 2007-10-03 PT PT78392164T patent/PT2066791E/pt unknown
- 2007-10-03 ES ES16184966T patent/ES2757723T3/es active Active
- 2007-10-03 ES ES07839216T patent/ES2391789T3/es active Active
- 2007-10-03 SI SI200731083T patent/SI2066791T1/sl unknown
- 2007-10-03 EP EP16184966.6A patent/EP3146982B1/en active Active
- 2007-10-03 HU HUE12157957A patent/HUE031182T2/en unknown
- 2007-10-03 EP EP19192274.9A patent/EP3632472A1/en active Pending
- 2007-10-03 AR ARP070104379A patent/AR063113A1/es active IP Right Grant
- 2007-10-03 ES ES12157957.7T patent/ES2607060T3/es active Active
- 2007-10-03 LT LTEP12157957.7T patent/LT2497500T/lt unknown
- 2007-10-03 CN CN201810575782.XA patent/CN108853517A/zh active Pending
- 2007-10-03 PT PT161849666T patent/PT3146982T/pt unknown
- 2007-10-03 LT LT16184966T patent/LT3146982T/lt unknown
- 2007-10-03 CN CNA200780038545XA patent/CN101528922A/zh active Pending
- 2007-10-03 SI SI200731873A patent/SI2497500T1/sl unknown
- 2007-10-03 EP EP12157957.7A patent/EP2497500B1/en active Active
- 2007-10-03 CN CN201610214446.3A patent/CN105770910A/zh active Pending
- 2007-10-03 SI SI200732128T patent/SI3146982T1/sl unknown
- 2007-10-03 HU HUE16184966A patent/HUE046709T2/hu unknown
2009
- 2009-04-03 US US12/417,910 patent/US9890394B2/en active Active
2016
- 2016-12-20 CY CY20161101325T patent/CY1118477T1/el unknown
2017
- 2017-12-29 US US15/858,303 patent/US10920245B2/en active Active

Also Published As

Publication number	Publication date
ES2607060T3 (es)	2017-03-29
DK2497500T3 (da)	2017-01-02
US20180230490A1 (en)	2018-08-16
PL2066791T3 (pl)	2013-02-28
ES2391789T3 (es)	2012-11-29
SI2066791T1 (sl)	2013-01-31
EP2497500A1 (en)	2012-09-12
WO2008042420A3 (en)	2008-07-03
HUE046709T2 (hu)	2020-03-30
EP3146982A1 (en)	2017-03-29
US20090286857A1 (en)	2009-11-19
EP2066791B1 (en)	2012-09-12
EP2497500B1 (en)	2016-09-28
PT3146982T (pt)	2019-10-31
PL2497500T3 (pl)	2017-07-31
SI2497500T1 (sl)	2017-01-31
EP3632472A1 (en)	2020-04-08
SI3146982T1 (sl)	2019-11-29
LT3146982T (lt)	2019-11-11
HUE031182T2 (en)	2017-06-28
EP2066791A4 (en)	2010-11-03
CY1118477T1 (el)	2017-07-12
EP2066791A2 (en)	2009-06-10
LT2497500T (lt)	2016-12-27
CN105770910A (zh)	2016-07-20
US9890394B2 (en)	2018-02-13
US10920245B2 (en)	2021-02-16
AR063113A1 (es)	2008-12-30
EP3146982B1 (en)	2019-08-21
WO2008042420A2 (en)	2008-04-10
CN108853517A (zh)	2018-11-23
ES2757723T3 (es)	2020-04-30
CN101528922A (zh)	2009-09-09
PT2066791E (pt)	2012-12-05
PT2497500T (pt)	2016-11-23

Publication	Publication Date	Title
DK2066791T3 (da)	2012-10-15	Genterapi for amyotrofisk lateralsklerose og andre rygmarvssygdomme
HUE044182T2 (hu)	2019-10-28	Génterápia amiotrófiás laterális szklerózis és más gerincvelõ-rendellenességek kezelésére
PL2056807T3 (pl)	2013-02-28	Leczenie chorób zakaźnych
IL186749A0 (en)	2008-02-09	Dihydrothienopyrimidines for the treatment of inflammatory diseases
PL2044111T3 (pl)	2015-02-27	Celowanie czynnika H dopełniacza do leczenia chorób
PL3424932T3 (pl)	2021-09-20	Boronoftalidy do zastosowania terapeutycznego
EP2041176A4 (en)	2010-07-21	ANTIBODY MOLECULES FOR HUMANES IL-17
GB0602178D0 (en)	2006-03-15	Therapeutic treatment
PL2056842T3 (pl)	2013-03-29	Modyfikowany galaktozyloceramid do leczenia chorób nowotworowych
DK2035369T3 (da)	2014-10-06	Terapeutiske
DK1993589T3 (da)	2014-01-06	Behandlinger for neurologiske sygdomme
EP2025347A4 (en)	2010-08-11	PROPHYLACTIC AND THERAPEUTIC AGENTS AGAINST CANCER
CY2016019I2 (el)	2016-10-05	Θεραπευτικη αγωγη της σκληρυνσης κατα πλακας (ms) me campath-1h
IL221251A0 (en)	2012-10-31	Read through inducer, and therapeutic agent for nonsense-mutation-type genetic diseases
ZA200908989B (en)	2011-03-30	Enhancement of the efficacy of therapeutic proteins
GB0608655D0 (en)	2006-06-14	Therapeutic Treatment
EP2026822A4 (en)	2012-07-04	TOPICAL TREATMENT FOR EYE SURGERY DISEASES
EP2019590A4 (en)	2011-08-03	METHODS FOR TREATING DISEASES INVOLVING STRESS-RELATED CONDITIONS AND CONDITIONS
GB0610909D0 (en)	2006-07-12	Therapeutic treatment
EP2059238A4 (en)	2011-04-06	THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS
ZA200904660B (en)	2010-04-28	Treatment of IL-1-Beta related diseases
GB0623740D0 (en)	2007-01-10	Treatment of disease
GB0622136D0 (en)	2006-12-20	Treatment of gastrointestinal diseases
GB0610376D0 (en)	2006-07-05	Therapeutic treatment
HK1135323A (en)	2010-06-04	Treatment of il-1-beta related diseases